IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Salivary Gland Neoplasm
Cancer Research UKmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Salivary Gland Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB Cancer Research UK | Phase 2/3 | B |
ALECTINIB Hoffmann-La Roche | Phase 2 | CCC |
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 Klus Pharma Inc. | Phase 1/2 | CCC |
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 Klus Pharma Inc. | Phase 1/2 | CCC |
Rimiducid Poseida Therapeutics, Inc. | Phase 1 | CC |
ava6000 Avacta Life Sciences Ltd | Phase 1 | CC |
P-Psma-101 Car-T Cells Poseida Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →